Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC IN TERMS OF EFFICACY AND SAFETY IN LONG-TERM STUDY

51-week clinical study compared Sandoz Proposed biosimilaradalimumab with reference medicine Humira®* in patients with moderate-to-severe psoriasis1 Sandoz proposed biosimilaradalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz is leading the way in addressing challenges around access to treatment for people living with immunological diseases  Sandoz, a […]



This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here

Share the post

SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC IN TERMS OF EFFICACY AND SAFETY IN LONG-TERM STUDY

×

Subscribe to Global Banking And Finance Review Magazine – Fin

Get updates delivered right to your inbox!

Thank you for your subscription

×